CClinicalTrials.gg
Not yet recruitingNCT07409779Updated Mar 25, 2026

Capsular Distension Versus Corticosteroid Injection in Adhesive Capsulitis

An interventional study of capsular distension and Betamethasone (Diprostene®) Injection in Adhesive Capsulitis of the Shoulder, sponsored by Faculty of Medicine of Tunis. Not yet recruiting at 1 site in Tunisia. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-03-25.

Sponsored by Faculty of Medicine of Tunis · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Adhesive capsulitis is a common and disabling shoulder condition characterized by pain and progressive limitation of range of motion. Capsular distension and intra-articular corticosteroid injection are commonly used therapeutic options, often combined with rehabilitation, but their comparative effectiveness remains debated.

The objective of this randomized controlled trial is to compare the efficacy and tolerance of ultrasound-guided capsular distension combined with rehabilitation versus intra-articular corticosteroid injection combined with rehabilitation in patients with adhesive capsulitis.

Outcomes will include shoulder pain, range of motion, functional disability, patient satisfaction, and procedure-related complications, assessed at short, mid, and long-term follow-up.

02

Conditions studied

  • Adhesive Capsulitis of the Shoulder

Browse trials for

Keywords

  • adhesive capsulitis
  • capsular distension
  • rehabilitation
  • corticosteroid
03

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age between 18 and 80 years
  • Ability to provide informed consent
  • Shoulder pain with Visual Analog Scale (VAS) ≥ 40/100
  • Limitation of external rotation \< 45° or \< 50% compared to the contralateral side
  • Clinically diagnosed adhesive capsulitis with normal shoulder radiography

Exclusion criteria

Exclusion Criteria:

  • Rotator cuff tear
  • Previous shoulder surgery
  • Cervico-brachial neuralgia
  • Pregnancy or breastfeeding
  • Poorly controlled diabetes
  • Coagulation disorders or anticoagulant therapy with INR > 3
  • Allergy to lidocaine
  • Inflammatory rheumatic diseases
  • Severe cardiovascular or hematological diseases
  • Active infection or immunodeficiency
  • Severe psychiatric disorders
  • Recent shoulder rehabilitation (within 1 week)
  • Intra-articular corticosteroid injection or hyaluronic acid injection within the last 6 months
  • Refusal to sign informed consent
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Capsular Distension

    Ultrasound-guided capsular distension with immediate mobilization followed by a standardized rehabilitation program.

    Procedure: capsular distension

  • Experimental
    Betamethasone (Diprostene®) injection

    Ultrasound-guided intra-articular injection of betamethasone (Diprostene®) into the glenohumeral joint, performed under sterile conditions, followed by a standardized rehabilitation program.

    Procedure: Betamethasone (Diprostene®) Injection

Interventions

  • Procedurecapsular distension

    Ultrasound-guided glenohumeral capsular distension followed by immediate mobilization then a standardized rehabilitation program.

  • ProcedureBetamethasone (Diprostene®) Injection

    Ultrasound-guided intra-articular Betamethasone (Diprostene®) Injection of the glenohumeral joint performed under sterile conditions, followed by a standardized rehabilitation program.

05

What researchers measure

Primary outcomes

  1. Shoulder Pain Intensity (Visual Analog Scale)

    Change in shoulder pain intensity assessed using a 100-mm Visual Analog Scale (VAS), where 0 indicates no pain and 100 indicates the worst imaginable pain.

    Time frame: Baseline, 1 month, 3 months, and 6 months

  2. Shoulder range of motion

    Change in active shoulder range of motion measured in degrees, including external rotation, internal rotation, abduction, and forward elevation.

    Time frame: Baseline, 1 month, 3 months, and 6 months

  3. Shoulder Pain and Disability Index (SPADI)

    Change in shoulder pain and disability assessed using the Shoulder Pain and Disability Index (SPADI), a validated 13-item questionnaire scored from 0 to 100, with higher scores indicating greater pain and disability.

    Time frame: Baseline, 1 month, 3 months, and 6 months

Secondary outcomes

  1. Patient Satisfaction Score

    Patient-reported satisfaction assessed using a numeric rating scale ranging from 0 to 10, where 0 indicates not satisfied at all and 10 indicates completely satisfied with the treatment.

    Time frame: 6 months

  2. Procedure-Related Complications

    Occurrence of immediate or delayed complications related to the procedures.

    Time frame: 1 month

  3. Rotator Cuff Interval Doppler Signal

    Presence of Doppler signal at the rotator cuff interval assessed by shoulder ultrasound, reported as present or absent.

    Time frame: Inclusion, 3 months ,6 months

  4. Coracohumeral Ligament Thickness

    Thickness of the coracohumeral ligament measured in millimeters using shoulder ultrasound.

    Time frame: Baseline, 3 months, and 6 months

  5. Glenohumeral Capsular Thickness

    Thickness of the glenohumeral joint capsule measured in millimeters using shoulder ultrasound at the axillary recess.

    Time frame: Baseline, 3 months, and 6 months

06

Study locations

1 site
  • Faculty of Medecine of Tunis
    Tunis, Tunis Governorate, Tunisia
    • Leila Rouached, assistant professor · Contact · leila.rouached@fmt.utm.tn · 0021653482262
    • Ines Mahmoud, Professor · Principal investigator
    • Kawther Ben Abdelghani, Professor · Principal investigator
    • Rim Dhahri, Professor · Principal investigator
    • Saoussen Miladi, associate professor · Principal investigator
    • Houda Ajlani, Rheumatologist · Principal investigator
    • Leila Rouached, Assistant professor · Principal investigator
    • Hiba Boussaa, assistant professor · Principal investigator
    • Yasmine Makhlouf, Assistant professor · Principal investigator
    • Olfa Jomaa, Assistant professor · Principal investigator
    • Hiba Ben Ayed, Assistant professor · Principal investigator
07

References and documents

Individual participant data

Plan to share: No — The IPD collected in this study will not be shared publicly. Data will be used exclusively by the study investigators for the purposes of this research.

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07409779
Lead sponsor
Faculty of Medicine of Tunis
Responsible party
Sponsor
First posted
Feb 13, 2026
Start date
Apr 1, 2026 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Mar 25, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion